jrnl7855

Publication Venue For

  • Potential kidney toxicity from the antiviral drug tenofovir: New indications, new formulations, and a new prodrug.  27:102-112. 2018
  • The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.  25:314-324. 2016
  • Endothelin-1 and the kidney: New perspectives and recent findings.  25:35-41. 2016
  • Pathophysiology of the chronic kidney disease - Mineral bone disorder.  24:303-309. 2015
  • Current status on the evaluation and management of the highly sensitized kidney transplant recipient.  24:570-575. 2015
  • Medical management of chronic kidney disease in the renal transplant recipient.  24:587-593. 2015
  • Pathogenesis of immunoglobulin A nephropathy.  22:287-294. 2013
  • Nitric oxide and the A and B of endothelin of sodium homeostasis.  22:26-31. 2013
  • Fibroblast growth factor 23 and the heart.  21:369-375. 2012
  • Increased serum phosphate and adverse clinical outcomes: Unraveling mechanisms of disease.  20:224-228. 2011
  • Mechanisms and consequences of salt sensitivity and dietary salt intake.  20:37-43. 2011
  • Uric acid: A novel mediator and marker of risk in chronic kidney disease?.  18:526-530. 2009
  • Tubuloglomerular feedback mechanisms in nephron segments beyond the macula densa.  18:57-62. 2009
  • Renin inhibition: Should it supplant ACE inhibitors and ARBS in high risk patients?.  17:484-490. 2008
  • Endothelin and NOS1/nitric oxide signaling and regulation of sodium homeostasis.  17:70-75. 2008
  • Vascular stenosis: Biology and interventions.  16:516-522. 2007
  • Effect of salt intake on progression of chronic kidney disease.  15:54-60. 2006
  • Hormonal and cytokine effects of uric acid.  15:30-33. 2006
  • Fabry disease: Diagnosis and management, with emphasis on the renal manifestations.  14:87-95. 2005
  • Management of paraproteinemic renal disease.  14:97-103. 2005
  • IgA nephropathy: An update.  13:171-179. 2004
  • A family of calcium-permeable channels in the kidney: Distinct roles in renal calcium handling.  11:555-561. 2002
  • Hormone replacement therapy and hypertension.  11:229-235. 2002
  • Genetic forms of human hypertension.  10:493-499. 2001
  • Interaction of syntaxins with epithelial ion channels.  9:523-527. 2000
  • Renal endothelin in hypertension.  9:157-164. 2000
  • Sodium transporters in health and disease.  6:372-376. 1997
  • Antihypertensive therapy in the era of evidence based medical practice: What to do until the facts are in.  5:159-161. 1996
  • Hypertension in postmenopausal women: Pathophysiology and management.  4:438-442. 1995
  • Hypertension in women.  4:204-207. 1995
  • Antihypertensive therapy in the context of total cardiovascular risk: the rational basis for therapeutic recommendations..  3:195-199. 1994
  • Neurologic consequences of hypertension and antihypertensive drug therapy..  3:228-235. 1994
  • Renal involvement in plasma cell dyscrasias..  2:246-252. 1993
  • The role of the sympathetic nervous system in hypertension..  2:265-273. 1993